We are continuously conducting evidence synthesis to inform national strategic decision-making. In the last quarter, we have published a number of reports and health technology assessments (HTAs), including the first of our generic justification decisions.

We are supporting the Department of Health, the National Screening Advisory Committee and the HSE in their decision making by reviewing topics such as:

• International review of the epidemiology of long COVID
• HTA of Domiciliary Invasive Ventilation for Adults with Spinal Cord Injuries
• Generic Justification Decision: 177 Lu oxodotreotide for the treatment of metastatic or inoperable gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

If you would like to find out more about the work of HIQA and the HTA team in their response to COVID-19, you can here.

The bulletin is updated quarterly and shared across our social media platforms.

If you would like to receive the bulletin to your inbox directly, you can request the bulletin from htanews@hiqa.ie.